The report provides current treatment practices, emerging drugs, individual therapy market share, current and projected size of the frontotemporal dementia (FTD) market from 2017 to 2030 segmented by seven main markets. The report also covers the current treatment practice / algorithm, market drivers, market barriers and unmet medical needs to best organize the opportunities and assess the underlying market potential.
The epidemiology of frontotemporal dementia (FTD) division provides information on the historical and current patient pool and the expected trend for seven main countries. It helps recognize the causes of current and projected trends by exploring numerous studies and opinions from key opinion leaders. This part of the report also provides the pool of patients diagnosed and their trends as well as the hypotheses retained. According to the editor, the total number of cases of frontotemporal dementia (FTD) prevalent in 7 MM was 76,499 in 2017.
The epidemiology of the disease covered in the report provides a historical and forecast epidemiology (prevalent diagnosed cases of FTD, prevalent cases of FTD by types, specific cases of primary progressive apahasia subtype and mutations associated with FTD) scenario of dementia frontotemporale (FTD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030.
This segment of the frontotemporal dementia report contains a detailed analysis of marketed drugs and drugs in the final phase (phase III and phase II). It also helps to understand the details of the clinical trial, the expressive pharmacological action, the agreements and collaborations, the details of the approval and patent and the latest news and press releases.
There is currently no disease-modifying treatment approved by the FDA (Food and Drug Administration) or EMA (European Medicines Agency) or PMDA (Pharmaceutical and Medical Products Agency) for the management of FTD. Current treatment strategies are primarily based on the off-label use of drugs for symptom management, and most therapies lack quality evidence from randomized, placebo-controlled clinical trials. These therapies are based on the modulation of neurotransmitter levels and do not target the underlying pathophysiology of FTD. The FTD drug market is classified according to drug classes such as selective serotonin reuptake inhibitors (Citalopram, Fluoxetine), antipsychotic agents, cholinesterase inhibitors (donepezil, rivastigmine and galantamine), receptor antagonists NMDA (Memantine) and benzodiazepines.
AL001 is the human monoclonal antibody 100% owned by Alector and designed to modulate progranulin, a regulator of immune activity in the brain with genetic links to multiple neurodegenerative disorders, including FTD, Alzheimer’s disease and Parkinson’s disease. It aims to increase the level of progranulin in humans by inhibiting a mechanism of degradation of progranulin. In August 2019, the U.S. Food and Drug Administration (FDA) has granted Alector an Orphan Drug Designation for the continued development of AL001.
The market outlook on frontotemporal dementia from the report helps to build a detailed understanding of the historical, current and projected market trend by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and the demand for better technology.
This segment provides a detailed breakdown of the market trend for each drug on the market and in terminal therapy by assessing their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action. , compliance rate, growing market need, increase in the number of pool patients, patient segment covered, planned launch year, competition with other therapies, brand value, their impact on the market and opinions of the main opinion leaders. The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first glance.
According to the editor, the frontotemporal dementia market in 7MM should undergo a major positive change during the study period (2017-2030). The frontotemporal dementia market is expected to increase with a CAGR of 21.41% for 7 MM during the study period. Among the 7MM, United States represents the largest FTD market size, compared to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
This section focuses on the absorption rate of potential drugs recently marketed or to be marketed during the 2017-2030 study period. The analysis focuses on market adoption by drugs; the treatment of patients by therapies and the sale of each drug.
This helps to understand the fastest adopting drugs, the reasons for the maximum use of new drugs and allows the comparison of drugs on the basis of market share and size, which will again be useful to study important factors in market adoption and to make financial and regulatory decisions.
Pipeline development activities
The report provides an overview of the different therapeutic candidates in phases II and III. It also analyzes the key players in frontotemporal dementia involved in the development of targeted therapies.
The proactive approach to reimbursement can have a positive impact both during the final stages of product development and well after the product is launched. In the report, we take reimbursement into account to identify economically attractive indications and market opportunities. When working with limited resources, the ability to select markets with the least barriers to repayment can be a business strategy and a critical price.
KOL – Views
To follow current market trends, we take the advice of KOLs and SMEs working in the field of frontotemporal dementia through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the treatment regimens of current and emerging therapies or the market trend of frontotemporal dementia. This will help customers in a possible new treatment to come by identifying the overall market scenario and unmet needs.
Competitive intelligence analysis
The publisher performs competitive and market intelligence analysis of the frontotemporal dementia market using various competitive intelligence tools which include – SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies, etc. The inclusion of the analysis depends entirely on the availability data.
Scope of the report
- The report covers the descriptive overview of frontotemporal dementia, explaining its causes, signs and symptoms, pathophysiology and currently available therapies
- A full overview was provided on the epidemiology and treatment of frontotemporal dementia in 7MM
- In addition, an all-inclusive account of current and emerging therapies for frontotemporal dementia is provided, as well as evaluation of new therapies, which will impact the current therapeutic landscape.
- A detailed review of the frontotemporal dementia market; historical and planned is included in the report, covering drug awareness in the 7MM
- Report provides benefit while developing business strategies, understanding the trends that shape and drive the global market for frontotemporal dementia
For more information on this drug pipeline report, visit https://www.researchandmarkets.com/r/o4sv5k
Research and markets also offer personalized research services offering targeted, comprehensive and personalized research.
Research and markets
Laura Wood, Senior Manager
For EST opening hours, call + 1-917-300-0470
For free calls to the U.S. and Canada + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
American fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and markets